Background Around 200 million adults in China have hypertension, but few are treated or achieve adequate control of their blood pressure. Available and affordable medications are important for successfully controlling hypertension, but little is known about current patterns of access to, and use of, antihypertensive medications in Chinese primary health care.
Introduction
An estimated 200 million adults in China have hypertension but fewer than 15% are treated. [1] [2] [3] [4] Moreover, among those who are treated, about two-thirds do not achieve adequate control of their blood pressure. [5] [6] [7] [8] Inadequate management of patients with hypertension might have substantial health and economical consequences; the sequelae of hypertension, including stroke and heart disease, are the leading causes of morbidity and mortality in China, 9, 10 and are associated with substantial expense to patients and the health system.
The successful management of hypertension in China requires, in addition to lifestyle and behavioural modifications, affordable and widely available antihypertensive medications prescribed appropriately in primary health-care settings, a main point of contact with the health system in China. Findings from studies have suggested low availability and high costs as major barriers to optimum use and adherence to essential antihypertensive medications, especially in low-income rural areas in China. 3, 11 The Chinese health reform in 2009 strengthened the role of primary health care that serves as gatekeeper to the health-care system. 12 The reform also introduced the National Essential Medicine Program that was designed to provide affordable and equitable basic health care for all by 2020. Pharmaceutical policy has also evolved quickly, such as allowances for primary health-care sites to procure non-essential medicines in 2014 and abolishment of the government price ceiling in 2015 (appendix). Although availability of medications increased after the National Essential Medicine Policy was launched, [13] [14] [15] little is known about current patterns of access to antihypertensive medications across Chinese primary health-care settings, where higher financial burdens and few medication choices might result in lower treatment and control rates. This information is essential for developing targets for interventions that are designed to improve national hypertension treatment and control. Accordingly, to address the need for information about the availability, cost, and prescription of antihypertensive medications in primary health-care settings across China, we analysed data from a national, government-funded study of the primary health-care system and a large national cardiovascular screening project. 16 Our study focused on all four types of primary health-care sites in China-community health centres and community health stations in urban areas, and township health centres and village clinics in rural areas-and also examined how the costs of antihypertensive medications were associated with the availability and prescription of antihypertensive medications, with a particular focus on lower-cost, guideline-recommended treatments.
Methods

Data source and study sample
We derived data on the availability, cost, and prescription of antihypertensive medications from the nationwide China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE) Million Persons Project (MPP) primary health-care survey, undertaken from November, 2016 through May, 2017. The design of this survey has been described previously. 17 Briefly, we established a nationwide epidemiological collaborative network of the China PEACE MPP, which consisted of 141 county or district-level regions from all 31 provinces in mainland China. 16 The MPP enrolled the eligible study sites according to the number of residents of the catchment area, population stability, local economical conditions, and geographical location. The PHC services are provided by community health centres and community health stations (one level below) in urban areas, and township health centres and village clinics (one level below) in rural areas (appendix). We surveyed 203 community health centres, 401 community health stations, 284 township health centres, and 2474 village clinics to quantify the care-delivery capacity and the quality of primary health care. The distribution of primary health care study sites sampled across rural and urban areas reflects the national ratio. 18 Data on hypertension treatment and control were derived from the cardiovascular risk screening programme of the China PEACE MPP, which up to June 20, 2017, had enrolled 1·7 million residents, aged 35 to 75 years, who had lived in 141 selected county-level or district-level regions for at least 6 months in the past year. The interview data from China PEACE MPP included information about the history of hypertension diagnosis and treatment, collected by face-to-face administration of a questionnaire. In total, 1·09 million people with information in the MPP lived in the 435 townships or communities that are the focus of this study. We linked the characteristics of primary healthcare sites with local population epidemiological data at the township or community level (ie, one level below county or district), China's 2015 National Census data,
Research in context
Evidence before this study To assess treatment and control of hypertension in China, we searched PubMed for English-language published articles and the China National Knowledge Infrastructure for Chinese-language articles, published before May, 2016, using the terms "primary health care", "pharmaceutical policy", "essential medication", "essential medicine", "hypertensive medication", OR "hypertension". We also reviewed references from the identified articles and other relevant articles and reports. Awareness, treatment, and control of hypertension were found to be low. The Chinese National Essential Medicine Program, a zero mark-up policy for essential medications, was implemented by all primary health-care sites in 2009 to meet residents' medication needs and reduce their out-of-pocket costs. However, we noted conflicting results for availability and cost, and few studies reported prescription patterns of antihypertensive medications. Previous studies were limited to specific regions, populations, and data sources.
Added value of this study
We used data from a national primary health-care study and a screening study of high risks for cardiovascular disease in China to depict the current status of availability, cost, and prescription patterns of antihypertensive medications in primary health-care settings in China. We collected the data directly from primary health-care sites, rather than analysing secondary data from other reports. We noted marked deficiencies in availability, cost, and prescription of hypertensive medications, and a few health-care pharmacies did not stock any antihypertensive medications. Village clinics and sites in the western region of China had the lowest availability. High-cost medications were more likely to be prescribed than low-cost medications, and high-value medications, those that are guideline-recommended and low-cost, were not preferentially prescribed.
Implications of all the available evidence
Our findings suggest that interventions to improve hypertension treatment and control in China will need to ensure that low-cost antihypertensive medications are adequately available in primary health-care settings. Implementation of the essential medicines policy at the local level is currently inadequate. Use of high-value medications might help to reduce patients' cost burden of hypertension treatment. March 31, 2016) , we collected information about each patient's age, sex, and diagnosis, which is routinely listed on the prescriptions, as well as the medication name, dosage, and administration. In primary healthcare sites with an electronic prescription system, relevant information was directly imported into a digital database. For sites without an electronic prescription system, we included the first 100 outpatient prescriptions in each 10-day period for the 12 months in our analysis (3600 total prescriptions during the study period). We scanned copies and trained staff to manually abstract relevant information, with double-entry methods included as a quality check to ensure an accuracy standard of at least 98%.
In MPP, blood pressure was measured twice during the interview, using a unified electronic blood pressure monitor (Omron HEM-7430; Omron Corporation, Kyoto, Japan) with standardised procedures. 21 Treatment was defined as the proportion of patients in the China PEACE MPP population with hypertension who selfreported use of antihypertensive medications at the baseline interview. Control was defined as the proportion of these patients with a blood pressure of less than 140/90 mm Hg at the baseline interview. Treatment and control of hypertension were assessed by aggregating participant data at the township or community level.
We obtained information on the characteristics of each primary health-care site, including workforce and use of information technology systems, through a survey of site leaders and health-care professionals. We focused on 62 oral medications by generic names listed in the database of guidelines for hypertension management, regardless of whether they were recommended, 2, 22, 23 and the essential medicine lists. 24 We categorised each of these medicines as angiotensin-converting-enzyme inhibitors (ACE inhibitors), angiotensin-receptor blockers, betablockers, calcium-channel blockers, diuretics, fixed-dose combination medications, traditional compound drugs, or centrally active drugs; each category was mutually exclusive (ie, a medicine in one category could not be categorised in another). We did not include alpha-blockers or alpha-beta blockers because of their scarcity in the primary care sector.
We ascertained the availability of each antihypertensive medication at any dose in the site pharmacy, calculated as the proportion of all participating sites with a specific antihypertensive medication or medication 
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Data are n (%), % (95% CI), or mean (SD). MPP=Million Persons Project. ··=not applicable. *The population is linked at the township or community level. †Among all patients with hypertension. Awareness was defined as self-reported diagnosis of hypertension at the baseline interview. The guideline recommends medicines based on clinical effectiveness. We used the 2014 guideline as a framework to guide our investigation of a wide range of anti hypertensive medications expected for routine use.
Statistical analysis
First, to examine availability, cost, and prescription of antihypertensive medications at different types of primary health-care sites, we calculated percentages for categorical variables, and mean (SD) or median (IQR) for continuous variables, as appropriate. To determine site-specific characteristics associated with the availability of antihypertensive medications, we fitted a mixed model final model included six characteristics other than the type of sites and regions-ie, the number of health-care professionals, licensed physicians, physicians with a medical bachelor degree (5-year medical education), physicians who took a continuing-education course in the past year, social insurances for contracted health-care professionals, and healthcare professionals who routinely used IT systems (appendix). Second, we modelled the prescribed medication as a function of its cost, both overall and in rural or urban subgroups. To address potential sampling variation and imbalances in numbers between electronic prescriptions and prescriptions taken from scanned copies, we adapted a resampling approach to undertake a simulation analysis with a non-parametric bootstrap, with replacement, method. 27, 28 Specifically, for prescription data taken from scanned copies, we randomly selected records with a sample size equal to the total number of records; for electronic prescription data, we randomly selected a sample size equal to the sample size of the prescription data from the scanned copy. We then appended the two resampled datasets together and fitted the mixed model to estimate the association between the medication's prescription and its cost. We repeated this process 10 000 times to obtain the distributions of the estimated associations and their 95% CIs. All analyses were done using SAS 9.4, and all statistical testing was two-sided, at a significance level of 0·05. The Fuwai Hospital Institutional Review Board approved the study; the site survey was deemed exempt; and informed consent was obtained from all MPP study participants.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding and lead authors had full access to all the data in the study, and all authors had final responsibility for the decision to submit for publication.
Results
The study sample included 3362 primary health-care sites (18·0% urban, 82·0% rural) across China (appendix). Township health centres constituted 8·4% of sites, village clinics 73·6%, community health centres 6·0%, and stations 11·9% (table 1). The 435 townships or communities, which collectively enrolled 1·09 million people in the China PEACE MPP, served as the study sample for determining hypertension treatment and control rates. The median sample size of participants at the township or community level was 2128 (IQR 1165-3103).
Among the 3362 PHC sites, the most widely available antihypertensives were calcium-channel blockers, of which nifedipine extended release was the most commonly stocked (table 2) .
The patterns of medication availability varied by site. Overall, 8·1% (273/3362, 95% CI 7·2-9·1) of primary health-care pharmacies did not have any antihypertensive with township or community as random effects and a logit-link function. The model included a spherical covariate structure to account for spatial autocorrelation and differences among townships or communities. The figure 2) .
The sites varied by treatment and control (appendix). The median risk-standardised treatment and control rates were 35·7% (IQR 19·6-52·1) and 8·3% (3·6-16·1), respectively. The worst 10% of sites had rates of 4·1% (1·6-5·8) and 1·1% (0·8-1·5), respectively, whereas the best 10% had rates of 72·5% (69·3-77·3) and 30·6% (26·5-35·4).
The cost of a medication was associated with being prescribed (figure 3, appendix), but not with its availability ( figure 3 ). On average, high-cost medications were more likely than low-cost medications to be prescribed in primary health-care sites. Low-cost medications accounted for 40·5% (95% CI 39·9-41·1) of the medications in the pharmacies. Of all the prescriptions, 12·6% (12·3-13·0) were for low-cost medications and 4·7% (4·4-4·9) were for diuretics, the lowest-cost medication.
Discussion
This national study of antihypertensive medications in China revealed marked deficiencies in their availability, cost, and prescription. First, hypertension medications are inconsistently available in primary health-care pharmacies across China, and one in 12 did not stock any antihypertensive medications. Second, despite the availability of low-cost antihypertensive medications, higher-cost medications were more often prescribed. In fact, the higher the cost of the medication, the more likely that it was prescribed; however, this did not necessarily mean that the most expensive drug was the one that was most frequently prescribed. The higher-cost medications did not represent medications with higher effectiveness.
This study adds to the scientific literature in several ways: it is the first national study of the availability, cost, and prescription of antihypertensive medications in China, involving all provinces. National policies with regard to essential medications and reimbursement might aim to improve access; 29 this study provides a contemporary assessment of the availability and use of antihypertensive therapies in primary health-care sites around the country and shows that deficiencies exist at the point of care. This study was based on actual investigations of the pharmacies and inspection of the prescriptions, and required government support, partnership with providers and administrators of primary health care, and site access to inspect pharmacies and examine prescriptions. The study did not depend on reports from the sites but, rather, involved direct data collection. Previous studies were limited to specific regions, populations, and data sources. 14, [30] [31] [32] The reasons for gaps in the availability and prescription of antihypertensive medications are not clear. Chinese national policies state that essential medications should be available and affordable. However, we uncovered problems in the inventory of antihypertensive medication that can be supplied to patients at primary health-care sites. Despite the national focus on blood pressure control-and the responsibility of many of the sites for hypertension management 33 -a substantial proportion of these pharmacies had no or only a few antihypertensive medications, especially the low-cost drugs.
14 The zero mark-up policy might be a possible contributor to our finding that high-value medications are not frequently prescribed. Initiated in 2009, this policy prohibits healthcare providers from selling essential medicines at prices higher than their wholesale cost. This policy reportedly exerted a large net effect on the revenue of village clinics, despite government subsidies being increased to compensate for revenue loss. 34, 35 These reforms have been suggested to have led to a less-reliable drug supply system in China; for instance, village clinics might no longer provide essential medicines at zero mark-up because of the absence of a profit. 36 With respect to drug-prescribing patterns, there has been an increase in the use of expensive medications since implementation of the Chinese National Essential Medicine Program. 11 Refinements to this policy might provide stronger incentives for the use of low-cost medications. Mandating the availability of medicines might not be sufficient to improve the prevalence of hypertension, but their availability is arguably a necessary component of disease management programmes. Additional studies are needed to carefully examine the effect of zero mark-up policies on access to antihypertensive medicines throughout Chinese primary health-care centres. 12, 37 Additionally, some patients and doctors might prefer antihypertensive traditional Chinese medicines, though their use was generally low in our study.
The implications of this study for hypertension management in China are substantial. The reality of care delivery in the clinics is not consistent with the health needs of the nation, and the deficiencies in primary care pharmacies have implications for patient health, as evidenced by suboptimal treatment and control rates. As such, interventions to improve hypertension treatment and control will need to focus not only on bolstering education, screening, and protocols, but also on ensuring that antihypertensive medications are adequately stocked by primary health-care pharmacies. 38 The adequacy of the medication inventory is not sufficient for progress in hypertension treatment and control, but it is certainly a fundamental component. Policy makers will need to ascertain why the aspiration of national policies is being stymied at a local level and probably thwarting efforts by practitioners to address hypertension in their patients.
The study has other important implications. The use of high-value medications-those that are guidelinerecommended and reasonably priced-should be a priority for all countries, especially those with few resources. 39 Our study showed that high-value medications are not preferentially used in Chinese primary health-care settings, even though there is no evidence that Percentage point increase in prescription for every 10 RMB increase in cost of medication higher-priced medications are more effective. 40 A greater emphasis on high-value antihypertensive medications has the potential to mitigate the cost burden of increasing the rates of treatment and providing more value to the country. In this respect, diuretics might be particularly cost-effective. Findings from previous studies have suggested that drugs such as chlorthalidone might even be better than drugs from other classes. 23 However, few comparative effectiveness studies of antihypertensive drugs have been done, 41 and it might be beneficial for China to prioritise such studies. Identifying the higherpriced medications with known marginal benefits over lower-cost alternatives would provide the basis for highquality and cost-efficient care.
The availability of antihypertensive medications varied among types of sites and economic regions, but inadequacies were not confined to certain types of centres. Site characteristics were not strongly associated with the availability of antihypertensive medications. This finding indicates the need for a broad-based strategy that would address problems that almost all types of primary health-care centres throughout China face.
Our study had several limitations. First, the study sites were not a representative sample despite spanning the entire country geographically and being so large in number. The treatment and control rates, however, were very similar to national estimates. 5 Second, we used a convenience sample and excluded people who were not residents. Those who were excluded would probably have had less access to care and would likely have had even lower control rates. Nevertheless, any inaccuracies in this study would be a bias toward the null, suggesting that our findings might have even underestimated the relationship. Of note, the prescription information reflected all prescriptions, including those provided to migrants. Third, this study focused on pharmacies in primary health-care sites, and people might go elsewhere for their prescriptions. However, half of private pharmacies impose fees that individuals must pay out of pocket. 42 Therefore, we expected that most patients would have a strong preference to obtain their medications from the clinic pharmacy. Future studies should build on these and other emerging primary datasets in China to examine the association between access to antihypertensive medicines and clinical outcomes, including control rates. Fourth, our choice of the 200 RMB threshold for cost might be arbitrary (ie, it was a general value that was not region-specific), and the threshold of 1% of annual disposal income might be higher for rural populations. Applying a lower-cost threshold, however, would further restrict the sample of medicines that could be defined as high-value, and lower the percentage of high-value drugs prescribed, further strengthening our findings. Finally, the inventory and prescription data that were collected covered slightly different periods. If any large-scale change in prescription drug inventories and prescribing behaviours are assumed to be marginal over the span of several months, the effect on this study from similar, albeit non-overlapping periods for data collection might be negligible.
In conclusion, this study revealed key obstacles to progress in mitigating hypertension in China. Despite advances in health-care coverage and policy to limit financial risks and improve health outcomes, 43 this study highlighted deficiencies in the availability, cost, and prescription of antihypertensive medications. Future policies aimed at alleviating the burden of hypertension in China, particularly through the work of primary health-care providers, will need to improve access to high-value antihypertensive medications.
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